Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
εPA-44 therapeutic hepatitis B vaccine plus entecavir versus entecavir alone in chronic hepatitis B
ChiCTR2100043708Phase 3Recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoint: Proportion of subjects with HBeAg/anti-HBe seroconversion. Started Apr 2021; status: recruiting.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100043708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043708.